2 | METHODS
| Trial design
We used patient data from the Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation (ORBIT-AF). ORBIT-AF is a national, multicenter, prospective registry of ambulatory AF patients.
The rationale and design of the registry has been previously described. 6 Primary care providers, cardiologist, and electrophysiologists enrolled patients in the clinic setting. Patients greater than 18 years of age with electrocardiographic evidence of atrial fibrillation who was not secondary to a reversible cause (eg, postoperative AF) were eligible for inclusion. Patients with a life expectancy less than 6 months and patients participating in a randomized trial of stroke prevention therapy were excluded. (Table 1) .
| Management of anticoagulation during device implantation and 30-day adverse events
The majority of patients undergoing CIED implant (n = 284, 64%) were managed with warfarin, whereas 14% (n = 60) were treated with NOACs Table 2) .
Rates of all-cause hospitalization did not differ between patients treated with interrupted vs uninterrupted oral anticoagulation (7% vs 4%, 
| DISCUSSION
We evaluated patterns of perioperative anticoagulation use during CIED implantation in a nationwide cohort of patients with AF. There Periprocedural anticoagulation management was highly variable.
We found that 35% of patients treated with a NOAC undergoing device implantation were managed with uninterrupted anticoagulation. Surprisingly, the rate of uninterrupted NOAC therapy was similar to the 36% rate observed in patients treated with warfarin.
Previous data from a large Canadian survey of 22 centers showed that 18% of implanting physicians continued a NOAC during CIED implantation. 8 These data are contemporaneous with our findings, and may be attributable to variation in practice patterns between countries (Figure 1 ). Gold and colleagues conducted a large meta-analysis across 13 studies in 5978 patients undergoing device implantation while on warfarin, 72% of which were anticoagulated due to AF. 15 Uninterrupted OAC during device implantation did not result in excess bleeding relative to no therapy, whereas patients managed with a heparin-bridging strategy had over 5-fold increased bleeding compared to continued OAC. 10 Another meta-analysis by Ghanbari 
| Limitations
This study has several important limitations. The ORBIT-AF registry was a prospective observational registry and patients were not randomized to treatment strategies. There were differences in baseline characteristics between patients treated with warfarin and NOACs, such as the increased use of aspirin in patients on NOACs. Statistical power was limited by the low number of patients in our registry who underwent device implantation on anticoagulation and number of complications across groups, so analyses controlling for possible confounders could not be performed. Anticoagulation strategies were categorized as uninterrupted or interrupted, but the precise timing of interruption prior to device surgery was not reported. Unfortunately, pocket hematoma formation was not a specifically reported adverse event. The centers Values are reported as number with percentage of total patients experiencing adverse event in parenthesis.
included in the ORBIT-AF registry may not be entirely representative of the general population of patients with AF in the United States, and our data may not be applicable to other regions of the world where practice patterns may differ. Finally, these data were obtained before the availability of NOAC reversal agents. It is not yet known how the availability of these agents will alter practice patterns.
| CONCLUSION
Management of anticoagulation during cardiac device implantation is variable, regardless of whether patients are treated with warfarin or NOACs. Although the majority of patients in our cohort who suffered a stroke/TIA had valvular disease, anticoagulation management in these patients did not differ from the general population. Despite data from prior studies demonstrating excess bleeding complications, patients with AF continue to receive bridging therapy. Adverse event rates 30 days after device implantation are rare regardless of strategy, and prospective randomized data are necessary to guide NOAC management in the device implant setting.
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